Immune response to type III group B streptococcal polysaccharide- tetanus toxoid conjugate vaccine

Journal of Clinical Investigation

Volumn 98, Issue 10, 1996, Pages 2308-2314

  Kasper, Dennis L ^a,e   Paoletti, Lawrence C ^a   Wessels, Michael R ^a,b   Guttormsen, Hilde Kari ^a   Carey, Vincent J ^a   Jennings, Harold J ^c   Baker, Carol J ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e CHANNING LABORATORY   (United States)

Author keywords

glycoconjugates; group B streptococci; maternal vaccination; neonatal infections; perinatal infections; women's health

Indexed keywords

BACTERIAL POLYSACCHARIDE; EPITOPE; SIALIC ACID; STREPTOCOCCUS TETANUS TOXOID CONJUGATE VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NEWBORN; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 0029852095     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119042     Document Type: Article

References (34)

1. Baker, C.J., and M.S. Edwards. 1995. Group B streptococcal infections. In Infectious Diseases of the Fetus and Newborn Infant. J.S. Remington and J.O. Klein, editors. W.B. Saunders, Philadelphia, PA. 980-1054.
2. Farley, M.M., R.C. Harvey, T. Stull, J.D. Smith, A. Schuchat, J.D. Wenger, and D.S. Stephens. 1993. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N. Engl. J. Med. 328:1807-1811.
3. Harrison, L.H., A. Ali, D.M. Dwyer, J.P. Libonati, M.W. Reeves, J.A. Elliott, L. Billmann, T. Lashkerwala, and J.A. Johnson. 1995. Relapsing invasive group B streptococcal infection in adults. Ann. Intern. Med. 123:421-427.
4. Jackson, L.A., R. Hilsdon, M.M. Farley, L.H. Harrison, A.L. Reingold, B.D. Plikaytis, J.D. Wenger, and A. Schuchat. 1995. Risk factors for group B streptococcal disease in adults. Ann. Intern. Med. 123:415-420.
5. Schuchat, A., K. Deaver-Robinson, B.D. Plikaytis, K. Zangwill, J. Mohle-Boetani, and J.D. Wenger. 1994. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. Pediatr. Infect. Dis. J. 13: 623-629.
6. Lancefield, R.C., M. McCarty, and W.N. Everly. 1975. Multiple mouse-protective antibodies directed against group B streptococci: special reference to antibodies effective against protein antigens. J. Exp. Med. 142:165-179.
7. Baker, C.J., and D.L. Kasper. 1976. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294:753-756.
8. Baker, C.J., and D.L. Kasper. 1985. Group B streptococcal vaccines. Rev. Infect. Dis. 7:458-467.
9. Baker, C.J., M.A. Rench, M.S. Edwards, R.J. Carpenter, B.M. Hays, and D.L. Kasper. 1988. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus. N. Engl. J. Med. 319:1180-1220.
10. Jennings, H.J., and R.K. Sood. 1994. Synthetic glycoconjugates as human vaccines. In Neoglycoconjugates: Preparation and Applications. Y.C. Lee and R.T. Lee, editors. Academic Press/New York. 325-361.
11. Wessels, M.R., A. Munoz, and D.L. Kasper. 1987. A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc. Natl. Acad. Sci. USA. 84:9170-9174.
12. Wessels, M.R., L.C. Paoletti, D.L. Kasper, J.L. DiFabio, F. Michon, K. Holme, and H.J. Jennings. 1990. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86:1428-1433.
13. Guttormsen, H.-K., C.J. Baker, M.S. Edwards, L.C. Paoletti, and D.L. Kasper. 1996. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J. Infect. Dis. 173:142-150.
14. Englund, J.A., W.P. Glezen, C. Turner, J. Harvey, C. Thompson, and G. Siber. 1995. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J. Infect. Dis. 171:99-105.
15. Wessels, M.R., and D.L. Kasper. 1989. Antibody recognition of the type 14 pneumococcal capsule. J. Exp. Med. 169:2121-2131.
16. Rodewald, A.K., A.B. Onderdonk, H.B. Warren, and D.L. Kasper. 1992. Neonatal mouse model of group B streptococcal infection. J. Infect. Dis. 166:635-639.
17. SAS Institute. 1990. SAS/STAT user's guide, version 6, volume 1. SAS Institute, Cary, NC.
18. Reed, G.F., B.D. Meade, and M.C. Steinhoff. 1995. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 96:600-603.
19. Wei, L.J. 1985. Combining dependent tests with incomplete repeated measurements. Biometrika. 72:359-364.
20. Mehta, C.R. 1991. StatXact: a statistical package for exact nonparametric inference. Am. Statistician. 45:74-75.
21. Paoletti, L.C., D.L. Kasper, F. Michon, J. DiFabio, H.J. Jennings, T.D. Tosteson, and M.R. Wessels. 1992. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J. Clin. Invest. 89:203-209.
22. Institutes of Medicine. 1985. Prospects for immunizing against Streptococcus group B. In New Vaccine Development: Establishing Priorities. Division of Health Promotion and Disease Prevention. Vol I. Diseases of importance in the United States. National Academy Press/Washington, DC. 424-438.
23. Schuchat, A., and J.D. Wenger. 1994. Epidemiology of group B streptococcal disease. Risk factors, prevention strategy, and vaccine development. Epidemiol. Rev. 16:374-402.
24. Centers for Disease Control and Prevention. 1996. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR. 45 (RR-7):1-25.
25. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. 1992. Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. Pediatrics. 90: 775-778.
26. Mohle-Boetani, J.C., A. Schuchat, B.D. Plikaytis, J.D. Smith, and C.V. Broome. 1993. Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis. JAMA (J. Am. Med. Assn.). 270:1442-1448.
27. Baker, C.J., D.L. Kasper, I.B. Tager, A. Paredes, S. Alpert, W.M. McCormack, and D. Goroff. 1977. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J. Clin. Invest. 59:810-818.
28. Baker, C.J., M.S. Edwards, and D.L. Kasper. 1981. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 68:544-549.
29. Hayrinen, J., S. Pelkonen, and J. Finne. 1989. Structural similarity of the type-specific group B streptococcal polysaccharides and the carbohydrate units of tissue glycoproteins: evaluation of possible cross-reactivity. Vaccine. 7:217-224.
30. Hornick, C.L., and F. Karush. 1972. Antibody affinity. III. The role of multivalence. Immunochemistry. 9:325-340.
31. Jennings, H.J., C. Lugowski, and D.L. Kasper. 1981. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochem. 20:4511-4518.
32. Wessels, M.R., L.C. Paoletti, J. Pinel, and D.L. Kasper. 1995. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Infect. Dis. 171:879-884.
33. Wessels, M.R., L.C. Paoletti, A.K. Rodewald, F. Michon, J. DiFabio, H.J. Jennings, and D.L. Kasper. 1993. Stimulation of protective antibodies against types Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 61:4760-4766.
34. Paoletti, L.C., M.R. Wessels, F. Michon, J. DiFabio, H.J. Jennings, and D.L. Kasper. 1992. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 60:4009-4014.